Abstract OT3-15-01: TBCRC-053: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

Joseph J. Connolly(Massachusetts General Hospital), Alice Ho(Breast Cancer Research Foundation), Carey K. Anders(Duke University), Laura M. Spring(Massachusetts General Hospital), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Antonio C. Wolff(Johns Hopkins University), Rachel Blitzblau(Duke Medical Center), Alastair M. Thompson(Baylor College of Medicine), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Ian E. Krop(Yale Cancer Center), Dana L. Casey(University of North Carolina at Chapel Hill), Elyssa N. Denault(Massachusetts General Hospital), Michele A. Gadd(Massachusetts General Hospital), Atif J. Khan(Memorial Sloan Kettering Cancer Center), Lisa K. Jacobs(Johns Hopkins University), Lisa A. Carey(University of North Carolina at Chapel Hill), José Pablo Leone(Harvard University), Alphonse G. Taghian(Massachusetts General Hospital), Tari A. King(Brigham and Women's Hospital), George Plitas(Memorial Sloan Kettering Cancer Center), E. Shelley Hwang(University of Bern), Cesar Augusto Santa-Maria(Sidney Kimmel Comprehensive Cancer Center), Yara Abdou(University of North Carolina at Chapel Hill), Gaorav P. Gupta(University of North Carolina at Chapel Hill), Jean L. Wright(University of North Carolina at Chapel Hill)
Cancer Research
March 1, 2023
Cited by 5


Related Papers